UK CRO hVIVO second Asia Pacific client in 2023

hVIVO has signed a new testing contract with an Asia-Pacific based drug maker, which it says is an indication of its growing regional client base.

The UK contract research organisation (CRO) shared minimal details of the £6.8 million contract last week, explaining it would test the unnamed client’s respiratory syncytial virus antiviral candidate using its human challenge study model.

The Phase IIa trial will take place at hVIVO’s quarantine facilities in Whitechapel in the UK starting in the first half of next year. The firm also said its dedicated recruitment arm, FluCamp, will be responsible for finding volunteers.

hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services for its broad and long-standing client base of biopharma companies.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    hVIVO plc

    More articles like this

    hVIVO plc

    Hvivo reports 44% Rise in earnings and Record Year in 2023

    Pharmaceutical services firm Hvivo, formerly Open Orphan, reported a 44pc rise in earnings in 2023 in a “record year across all financial and operational metrics.” Earnings before interest, taxes, depreciation and amortisation (Ebitda) increased to £13m

    hVIVO plc

    hVIVO Investor Conference

    hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials,

    hVIVO plc

    hVIVO enters 2024 with 90% of revenue guidance already contracted

    hVIVO plc (LON:HVO), the world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced an unaudited trading update for the year ended 31 December 2023. Highlights • Full year revenue of £56.0 million,